The 20 Best Muscle Invasive Bladder Cancer Doctors Near Me in Ashtabula, OH

Dr. Mark A. Preston is a urologic surgeon at Brigham and Women’s Hospital and Associate Professor of Surgery at Harvard Medical School. Dr. Preston received his Medical Degree from the University of Ottawa in Canada, where he also completed his residency training in Urology. He completed a three-year accredited fellowship in Urologic Oncology at Massachusetts General Hospital including a Masters of Public Health from the Harvard School of Public Health with a concentration in clinical effectiveness. He is board certified in Urology.Dr. Preston’s clinical interests include urologic oncology (bladder, kidney, prostate and testicular cancer) and minimally invasive surgery. Dr. Preston’s research focuses on the epidemiology of prostate and kidney cancer risk with an emphasis on predictive biomarkers and pharmacoepidemiology. Dr. Preston is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Cystectomy, and Prostatectomy. Dr. Preston is board certified in Urology.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Bladder Reconstruction, and Nephrectomy. Dr. Hoffman is board certified in American Board Of Internal Medicine.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Kates is board certified in American Board Of Urology.

Nima Almassi is an Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 20 years. Dr. Almassi is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy. Dr. Almassi is board certified in American Board Of Urology, 2022.

Dr. Mossanen is a graduate of the University of California, Los Angeles (UCLA) in Los Angeles, CA and received his medical degree from the David Geffen School of Medicine at UCLA. He also holds a Master of Public Health from the Harvard T.H. Chan School of Public Health in Boston, MA. Dr. Mossanen completed a residency in Urology from the University of Washington in Seattle, WA followed by a fellowship in Urologic Oncology in the Combined Harvard Urologic Oncology Fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Mossanen has been board certified by the American Board of Urology since 2020.His research and clinical interests include: bladder cancer, kidney cancer, kidney masses/cysts, laparoscopic surgery, penile cancer, prostate cancer, robotic surgery, testicular cancer. Dr. Mossanen is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Penile Cancer, Cystectomy, and Nephrectomy. Dr. Mossanen is board certified in Urology.

Dr. Graeme Steele is The Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women’s Hospital, surgical oncologist at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School. He received his medical degree from the University of the Witwatersrand and completed his internship in general surgery at Johannesburg Hospital. He completed residencies in general surgery and urology at the University of Witwatersrand Medical School in Johannesburg, South Africa, and became head of their Department of Urology Medical School.In 1995, he moved to Boston and completed his urology residency at the Harvard Urology Residency Program and received his fellowship in urology at Brigham and Women’s Hospital. Dr. Steele is board certified in urology.The author of numerous clinical publications, Dr. Steele has conducted research studies focusing on benign prostatic hyperplasia, urodynamic evaluation, bladder cancer, urinary cancer and testicular cancer. His clinical specialties include: urinary incontinence, urodynamic studies, urologic oncology and voiding dysfunction. Dr. Steele is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Vasectomy, and Orchiectomy. Dr. Steele is board certified in Urology.

Joshua Meeks is an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 21 years. Dr. Meeks is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery. Dr. Meeks is board certified in American Board Of Urology - Urology (Certified).

. Dr. Bermejo is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Familial Prostate Cancer, Ureteroscopy, and Reconstructive Urology Surgery.

. Dr. Tongco is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Renal Oncocytoma, UPJ Obstruction, Muscle Invasive Bladder Cancer, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Tongco is board certified in American Board Of Urology.

"Dr. Grant Taylor has been practicing urology in the Tri-Cities area since 2005. He says, ""We love the people in this area and the beauty around us. We enjoy outdoor activities, and this area affords us many opportunities to get outside."" Dr. Taylor's personal philosophy for treating patients is, ""Listen first and understand why they are here seeing us and the impact this issue has on them. This allows us to have aligned goals for their care."" He says, ""We all have difficult days in our lives. This is a sacred space that we as physicians are in with our patients, and we have the privilege of walking that with them and providing the kind of care we would want for our family.". Dr. Taylor is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Renal Oncocytoma, Urinary Tract Infection in Children, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Taylor is board certified in American Board Of Urology.

. Dr. Beaird is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses UPJ Obstruction, Urinary Tract Infection in Children, Perirenal Abscess, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Beaird is board certified in American Board Of Urology.

Alex Zacharias is a Urologist practicing medicine in Milwaukee, Wisconsin. Dr. Zacharias is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Reconstructive Urology Surgery, and Ureteroscopy. Dr. Zacharias is board certified in American Board Of Urology.

. Dr. Mcgoldrick is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Enlarged Prostate (BPH), Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Prostate Cancer, and Ureteroscopy.

James Griffin is a Urologist practicing medicine in Elgin, Illinois. Dr. Griffin is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Perirenal Abscess, Boils, Urinary Tract Infection in Children, Ureteroscopy, and Prostatectomy. Dr. Griffin is board certified in American Board Of Urology.

Matthew Wszolek is a Urologist practicing medicine in Danvers, Massachusetts. Dr. Wszolek is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy. Dr. Wszolek is board certified in Urology.

Thomas Guzzo is a Urologist practicing medicine in Philadelphia, Pennsylvania. Dr. Guzzo is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Cystectomy. Dr. Guzzo is board certified in Urology, 2011. Dr. Guzzo is currently accepting new patients.

Rohit Jain is an Endocrinologist practicing medicine in Washington, Washington, D.c.. Dr. Jain is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Penectomy, and Nephrectomy.

. Dr. Rogers is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses UPJ Obstruction, Hydronephrosis, Obstructive Uropathy, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Rogers is board certified in American Board Of Urology.